Abbott Laboratories has reported stronger-than-expected quarterly sales, helped by growth of its Humira arthritis drug and sales of low-cost generics in emerging markets.

However, shares in the pharmaceutical group fell 1.3 per cent, hurt by the company’s forecast that pricing pressures and other factors will lead to slightly lower second-quarter sales of vascular products compared with the first quarter. – (Reuters)